Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value products for
gene expression analysis, today announced the expansion of its product offering
to include LNA™ products for the research and development of RNA targeted
medicine including LNA™ as the active pharmaceutical ingredient.

The first new products being offered include the following:

-- oxy-LNA™ amidites in kilogram quantities
-- LNA™ oligonucleotides in gram quantities
-- miRCURY LNA™ microRNA Inhibitors in gram quantities

Exiqon can now also offer fully paid up, non-exclusive, manufacturing licenses
to customers who want to manufacture or have manufactured oxy-LNA™ amidites for
their research programs. Exiqon does not grant licenses to the manufacturing,
research, development or sale of LNA™ based drugs for clinical trials or
otherwise.

In a comment, Senior Vice President Sales & Marketing, Dr. Henrik M.
Pfundheller said: “We are excited to expand our product offering following
clarification that Santaris Pharma a/s does not have exclusive rights to supply
products for the research and development of LNA™ based drugs. Next generation
sequencing technology has revealed the complexity of the transcriptome,
however, the biological functionality of the RNA molecules are by far not
understood. With these products, Exiqon can now supply customers wishing to
conduct high throughput target identification and target validation studies and
eventually validate such targets in vivo.”

More information is available at Exiqon's website: http://www.exiqon.com/

Additional information:
Lars Kongsbak, CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)

See the full press release in the attached PDF or at
www.exiqon.com/investor/portal.

PressRelease_Oct_RD_products.pdf